BCL2L1 and plasma cell myeloma: The first selective Bcl-2 inhibitor was navitoclax (targets Bcl-2, Bcl-xL, and Bcl-W), followed by Obatoclax (targets Bcl-2, Bcl-xL, Mcl-1, and Bcl-W) and venetoclax (selectively targets Bcl-2), with the latter being (probably) the most well-known, due to its success, and favorable safety profile, in the treatment of chronic lymphocytic leukemia, acute myeloid leukemia, some subtypes of lymphoma and multiple myeloma [25].